parkinson’s disease paul tuite, md university of minnesota director of movement disorders
DESCRIPTION
Parkinson’s Disease Paul Tuite, MD University of Minnesota Director of Movement Disorders. Parkinson’s disease (PD). Early Clinical Features Tremor Slowness Stiffness Stooped posture Altered gait Small handwriting Softened voice Others. Epidemiology of PD. Incidence - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Parkinson’s Disease Paul Tuite, MD University of Minnesota Director of Movement Disorders](https://reader036.vdocument.in/reader036/viewer/2022062408/568136e3550346895d9e7cb3/html5/thumbnails/1.jpg)
Parkinson’s Disease
Paul Tuite, MDUniversity of Minnesota
Director of Movement Disorders
![Page 2: Parkinson’s Disease Paul Tuite, MD University of Minnesota Director of Movement Disorders](https://reader036.vdocument.in/reader036/viewer/2022062408/568136e3550346895d9e7cb3/html5/thumbnails/2.jpg)
Parkinson’s disease (PD)
Early Clinical FeaturesTremorSlownessStiffnessStooped postureAltered gaitSmall handwritingSoftened voiceOthers
![Page 3: Parkinson’s Disease Paul Tuite, MD University of Minnesota Director of Movement Disorders](https://reader036.vdocument.in/reader036/viewer/2022062408/568136e3550346895d9e7cb3/html5/thumbnails/3.jpg)
Epidemiology of PD
• Incidence– 5-24/ 105 worldwide (USA: 20.5/105)– Incidence of PD rising slowly with aging population
• Prevalence– 57-371/105 worldwide (USA/Canada 300/105)– 35%-42% of cases undiagnosed at any time
• Onset– mean PD 62.4 years– rare before age 30; 4-10% cases before age 40
www.wemove.org
![Page 4: Parkinson’s Disease Paul Tuite, MD University of Minnesota Director of Movement Disorders](https://reader036.vdocument.in/reader036/viewer/2022062408/568136e3550346895d9e7cb3/html5/thumbnails/4.jpg)
Risk Factors
• Definite: Old age
• Highly likely: MZ co-twin with early-onset PD
• Probable: Positive family history
• Possible: Herbicides, pesticides, heavy metals, proximity to industry, rural residence, well water, repeated head trauma, etc.
• Possible protective effect: Smoking
www.wemove.org
![Page 5: Parkinson’s Disease Paul Tuite, MD University of Minnesota Director of Movement Disorders](https://reader036.vdocument.in/reader036/viewer/2022062408/568136e3550346895d9e7cb3/html5/thumbnails/5.jpg)
Black line is age related loss
A. Toxin causes rapid loss of neurons at exposure
B. Genetic cause with variable rates of loss of neurons depending on the gene
C. Genetic and toxic model A H V Schapira; BMJ 1999;318:311-314
![Page 6: Parkinson’s Disease Paul Tuite, MD University of Minnesota Director of Movement Disorders](https://reader036.vdocument.in/reader036/viewer/2022062408/568136e3550346895d9e7cb3/html5/thumbnails/6.jpg)
Genetics of PD
• PARK1: (dominant), 4q21: alpha-synuclein • PARK2: (mainly recessive) 6q25-q27: Parkin • PARK3: (dominant, reduced penetrance) 2p13 • PARK4: (dominant, early onset) 4p15 • PARK5: (susceptibility gene) 4p14: UCH-L1 • PARK6: (recessive) 1p35-p36 • PARK7: (recessive) 1p36 • PARK8: (dominant) 12p11 • PARK9: (Kufor-Rukeb syndrome; recessive) 1p36 • PARK10: (susceptibility gene) 1p32 • FTDP17: (susceptibility gene) 17q21: Tau
![Page 7: Parkinson’s Disease Paul Tuite, MD University of Minnesota Director of Movement Disorders](https://reader036.vdocument.in/reader036/viewer/2022062408/568136e3550346895d9e7cb3/html5/thumbnails/7.jpg)
The Scientist 1997
![Page 8: Parkinson’s Disease Paul Tuite, MD University of Minnesota Director of Movement Disorders](https://reader036.vdocument.in/reader036/viewer/2022062408/568136e3550346895d9e7cb3/html5/thumbnails/8.jpg)
PD & Environmental Factors
Increased Risk– Pesticides
• Paraquat• Organochlorines• Carbamates
– Welding– Miners
Decreased Risk– Coffee consumption
• ?Caffeine
– Smoking• Nicotine
– MAO B inhibition
– CYP2D6
![Page 9: Parkinson’s Disease Paul Tuite, MD University of Minnesota Director of Movement Disorders](https://reader036.vdocument.in/reader036/viewer/2022062408/568136e3550346895d9e7cb3/html5/thumbnails/9.jpg)
Genetics Environment
Mitochondria Complex I Defects
Protein Accumulation
OxidativeStress
ExcitotoxicityAbnormal
ProteinDegradation
Cell Death
Betarbet et al. Brain Path 2002;12:499-510.
![Page 10: Parkinson’s Disease Paul Tuite, MD University of Minnesota Director of Movement Disorders](https://reader036.vdocument.in/reader036/viewer/2022062408/568136e3550346895d9e7cb3/html5/thumbnails/10.jpg)
Mitochondria
![Page 11: Parkinson’s Disease Paul Tuite, MD University of Minnesota Director of Movement Disorders](https://reader036.vdocument.in/reader036/viewer/2022062408/568136e3550346895d9e7cb3/html5/thumbnails/11.jpg)
Complex I Mitochondrial Inhibitors
Betarbet et al. Brain Path 2002;12:499-510.
![Page 12: Parkinson’s Disease Paul Tuite, MD University of Minnesota Director of Movement Disorders](https://reader036.vdocument.in/reader036/viewer/2022062408/568136e3550346895d9e7cb3/html5/thumbnails/12.jpg)
ROTENONE
![Page 13: Parkinson’s Disease Paul Tuite, MD University of Minnesota Director of Movement Disorders](https://reader036.vdocument.in/reader036/viewer/2022062408/568136e3550346895d9e7cb3/html5/thumbnails/13.jpg)
Betarbet et al. Brain Path 2002;12:499-510.
![Page 14: Parkinson’s Disease Paul Tuite, MD University of Minnesota Director of Movement Disorders](https://reader036.vdocument.in/reader036/viewer/2022062408/568136e3550346895d9e7cb3/html5/thumbnails/14.jpg)
GAO 2003 inflamm in PD TIPS
![Page 15: Parkinson’s Disease Paul Tuite, MD University of Minnesota Director of Movement Disorders](https://reader036.vdocument.in/reader036/viewer/2022062408/568136e3550346895d9e7cb3/html5/thumbnails/15.jpg)
Neurorestoration
Neuroprotection
Rate of development of disease
A H V Schapira; BMJ 1999;318:311-314
THERAPIES UNDER DEVELOPMENT